Monoclonal antibodies are an exciting advance in the treatment of lymphoma. They are safe and well-tolerated, and exhibit little cross-resistance with conventional chemotherapeutic agents. In indolent lymphomas, antibody therapy has shown useful response rates, both as first-line therapy and in relapsed disease. Follicular lymphomas appear to be particularly sensitive to rituximab, and chronic lymphocytic leukaemia to alemtuzumab. In aggressive lymphomas, the addition of rituximab to CHOP chemotherapy significantly lengthens disease-free and overall survival compared to CHOP alone as first-line therapy. Newer agents, including radiolabelled antibodies, immunotoxin-linked antibodies and antibodies against novel target antigens are showing promise in phase I and II trials in a variety of clinical settings.

中文翻译：

---

淋巴瘤的单克隆抗体治疗。

单克隆抗体是淋巴瘤治疗中令人兴奋的进展。它们安全且耐受性好，与常规化学治疗剂几乎没有交叉耐药性。在惰性淋巴瘤中，抗体治疗已显示出有用的反应率，无论是作为一线治疗还是在复发性疾病中。滤泡性淋巴瘤似乎对利妥昔单抗特别敏感，而慢性淋巴细胞性白血病对阿仑单抗则特别敏感。在侵袭性淋巴瘤中，与单独作为一线治疗的CHOP相比，在CHOP化疗中添加利妥昔单抗可显着延长无病生存期和总体生存期。新型试剂，包括放射性标记的抗体，免疫毒素连接的抗体和针对新型靶抗原的抗体，已在各种临床环境的I和II期试验中显示出希望。